Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 13/20 | 0.72 |
| ▸ | KCNQ3 | O43525 | 10/20 | 0.72 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824695 | 0.82 | KCNQ2 (0.56) | KCNQ2KCNQ3MAPTKDM4EALDH1A1 | |
| SCHEMBL970263 | 0.82 | KCNQ2 (0.56) | KCNQ2KCNQ3MAPTKDM4EALDH1A1 | |
| SCHEMBL13316848 | 0.80 | SMN1; SMN2 (0.54) | KCNQ2KCNQ3MAPTKDM4EALDH1A1 | |
| SCHEMBL3112479 | 0.79 | KCNQ3 (0.55) | KCNQ2KCNQ3MAPTMAPK1KDM4E | |
| SCHEMBL31322200 | 0.77 | KCNQ2 (0.47) | KCNQ2KCNQ3KCNQ4KCNQ5KDM4E | |
| SCHEMBL749463 | 0.76 | KCNQ2 (0.73) | KCNQ2KCNQ3 | |
| SCHEMBL4945050 | 0.76 | KCNQ2 (0.55) | KCNQ2KCNQ3MAPTLIPEALDH1A1 | |
| SCHEMBL3101326 | 0.76 | PIK3CA (0.49) | KCNQ2KCNQ3MAPTALDH1A1 | |
| SCHEMBL3677701 | 0.75 | KCNQ2 (0.53) | KCNQ2KCNQ3 | |
| SCHEMBL14271380 | 0.74 | KCNQ2 (0.53) | KCNQ2KCNQ3MAPTLIPEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2185149-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. Lundbeck A/S (DK) | 2010-05-19 | — | — | EP | claimed |
| US-7683058-B2 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2010-03-23 | — | — | US | claimed |
| WO-2009015667-A1 | USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | H. LUNDBECK A/S (DK) | 2009-02-05 | — | — | WO | claimed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | claimed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | claimed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2554162-A1 | Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia | H. Lundbeck A/S (DK) | 2013-02-06 | — | — | EP | disclosed |
| EP-1937653-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H.Lundbeck A/S (DK) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007090409-A1 | USE OF KCNQ-OPENERS FOR THREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA | H. LUNDBECK A/S (DK) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065449-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS KCNQ POTASSIUM CHANNELS OPENERS | H. LUNDBECK A/S (DK) | 2007-06-14 | — | — | WO | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
| US-20070066612-A1 | Substituted pyrimidine derivatives | H. LUNDBECK A/S (DK) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066612-A1 | Substituted pyrimidine derivatives | DPYD, TYMP, TYMS | KCNQ2 3538/4885KCNQ3 3903/4885KCNQ4 3983/4885 |
| US-20100256145-A1 | USE OF KCNQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED | KCNQ2, KCNQ4, KCNQ1 | KCNQ2 1/4885KCNQ3 4/4885KCNQ4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.